Thr230
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr230  -  TRF2 (human)

Site Information
HMSKDPttQkLRNDL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 456963

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 3 ) , immunoprecipitation ( 3 ) , phospho-antibody ( 1 , 3 ) , phosphopeptide mapping ( 3 ) , western blotting ( 1 , 3 )
Disease tissue studied:
brain cancer ( 3 ) , glioblastoma ( 3 ) , glioma ( 3 ) , fibrosarcoma of soft tissue ( 1 , 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
HMGA2 (human) ( 1 )
Treatments:
caffeine ( 3 ) , etoposide ( 3 ) , ionizing_radiation ( 3 ) , wortmannin ( 3 )

Downstream Regulation
Effects of modification on TRF2:
intracellular localization ( 3 )

References 

1

Natarajan S, et al. (2016) High Mobility Group A2 protects cancer cells against telomere dysfunction. Oncotarget 7, 12761-82
26799419   Curated Info

2

Her YR, Chung IK (2013) p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. Nucleic Acids Res 41, 2267-83
23307557   Curated Info

3

Tanaka H, et al. (2005) DNA damage-induced phosphorylation of the human telomere-associated protein TRF2. Proc Natl Acad Sci U S A 102, 15539-44
16223874   Curated Info